FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

Ipamorelin

NNC 26-0161

Growth Hormone Secretagogues

Ipamorelin is a highly selective pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor to stimulate pulsatile GH release from the anterior pituitary. Developed by Novo Nordisk in the 1990s, it is distinguished from other GHRPs by its remarkable selectivity, producing GH release without significantly affecting cortisol, prolactin, or aldosterone levels. It is considered the most well-tolerated GHRP available and is a cornerstone of modern GH optimization research protocols.

作用机制

Selective growth hormone secretagogue receptor (GHSR) agonist. Stimulates pituitary GH release with minimal effect on cortisol, prolactin, or ACTH. One of the most selective ghrelin mimetics available, producing clean GH pulses without appetite stimulation.

研究协议

仅供研究使用,非医疗建议。

Research protocols use 100-300mcg 2-3 times daily via subcutaneous injection. Best administered on an empty stomach. Often combined with CJC-1295 for synergistic GH release. Cycles of 8-16 weeks.

研究笔记

Clinical Research Status

Ipamorelin completed Phase 2 clinical trials for post-operative ileus (gut motility recovery) but was not advanced to approval. Published human studies confirm dose-dependent GH release with minimal effect on other pituitary hormones. It remains widely used in clinical research and anti-aging medicine despite lacking FDA approval for any indication.

Key Published Findings

Studies demonstrate that Ipamorelin produces GH release comparable to GHRP-6 and GHRP-2 at equivalent doses without the cortisol and prolactin elevation seen with those compounds. Research shows it does not significantly stimulate appetite (unlike GHRP-6 and hexarelin) due to weaker ghrelin receptor activation in appetite centers. Clinical trials documented improved bowel recovery time in post-surgical patients.

Safety Profile

Ipamorelin has the cleanest side effect profile among all GHRPs, with minimal reports of water retention, hunger stimulation, or cortisol elevation at standard doses. Transient headache, flushing, and mild dizziness may occur in the first 1-2 weeks of use. No significant adverse cardiovascular or metabolic effects have been documented in published trials at therapeutic doses.

Drug Interactions & Contraindications

Should not be used concurrently with somatostatin or its analogs. Caution advised when combining with insulin or insulin secretagogues due to GH's diabetogenic effects. Contraindicated in active malignancy and untreated pituitary tumors. May reduce efficacy of glucocorticoids through GH-mediated cortisol suppression at high doses.

Comparison to Related Compounds

Compared to GHRP-6, Ipamorelin produces equivalent GH release without significant hunger or cortisol elevation. Compared to GHRP-2, it has slightly lower maximal GH output but substantially fewer side effects. Hexarelin produces the highest GH response among GHRPs but causes significant cortisol/prolactin release and desensitizes within weeks, making Ipamorelin preferred for longer protocols.

Community Observations

Standard research dosing is 100-300mcg subcutaneously 1-3 times daily, typically combined with Modified GRF(1-29) at equal doses for synergistic GH release. Most commonly administered before sleep to augment the natural nocturnal GH pulse. Users consistently report improved sleep quality, recovery, and gradual body composition improvements with minimal side effects over 3-6 month protocols.

半衰期

~2 hours

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C up to 24 months.

复溶后

Refrigerate 2-8C. Use within 21 days.

美国法律状态

Research chemical (not FDA-approved)

又称作

NNC 26-0161

常见问题

什么是 Ipamorelin?

Ipamorelin is a highly selective pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor to stimulate pulsatile GH release from the anterior pituitary. Developed by Novo Nordisk in the 1990s, it is distinguished from other GHRPs by its remarkable selectivity, producing GH release without significantly affecting cortisol, prolactin, or aldosterone levels. It is considered the most well-tolerated GHRP available and is a cornerstone of modern GH optimization research protocols.

Ipamorelin 如何起作用?

Selective growth hormone secretagogue receptor (GHSR) agonist. Stimulates pituitary GH release with minimal effect on cortisol, prolactin, or ACTH. One of the most selective ghrelin mimetics available, producing clean GH pulses without appetite stimulation.

Ipamorelin 在美国的监管状态是什么?

Research chemical (not FDA-approved)

Ipamorelin 的半衰期是多少?

~2 hours

Ipamorelin 还有哪些名称?

NNC 26-0161

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明